To ensure the success of future clinical trials, product positioning in the market, and expedite the overall clinical trial timeline, the company submitted, on October 5, 2023, a revised protocol to the U.S. FDA for the core group clinical trial. In the modified protocol, all participants in the core group trial will be combined and executed injections every two months to obtain a sufficient sample size for Phase 2 clinical trials; this might accelerate entry into Phase 3 clinical trials by one year and expedite the drug's path to market.